Tech Company Financing Transactions
Circle Pharma Funding Round
On 9/3/2024, Circle Pharma raised $90 million in Series D funding from The Column Group, Euclidean Capital and Nextech Invest.
Transaction Overview
Company Name
Announced On
9/3/2024
Transaction Type
Venture Equity
Amount
$90,000,000
Round
Series D
Investors
The Column Group (Lead Investor) (Peter Svennilson)
Nextech Invest (Thilo Schroeder)
Proceeds Purpose
The company intends to use the funds to fund the clinical development of CID-078, its cyclin A/B RxL inhibitor, and to support the development of its portfolio of discovery programs built with its MXMO macrocycle platform.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
681 Gateway Blvd. LGL 3rd Floor
San Francisco, CA 94080
USA
San Francisco, CA 94080
USA
Phone
Website
Email Address
Overview
We design and develop bioavailable macrocyclic peptide therapeutics against important clinical targets. We do this by applying a computational structure-based design approach that combines physics (conformational modeling), chemistry (innovative molecular components) and biology (protein target structure and function).
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
David Earp
Chief Scientific Officer
Rajinder Singh
Co-Founder
Matthew Jacobson
Co-Founder
Scott Lokey
Vice President
James Aggen
VP - Operations
Amy Cowgill
VP - R & D
Pablo Garcia
VP - R & D
Constantine Kreatsoulas
Browse more venture capital transactions:
Prev: 9/3/2024: AcuraStem venture capital transaction
Next: 9/3/2024: Lendmark Financial Services venture capital transaction
Share this article
Where The Data Comes From
We record every notable VC transaction. VC investment data records reported here are derived from news reports and company announcements. The information comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs